Therma Bright Inc., formerly known as Jenex Corporation, received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). The Company received approval for the above claims from FDA (United States) in 1997. (Note:  510K in the name of The Jenex Corporation is currently not licensed in the US under Therma Bright Inc. The Company expects to transfer the 510K from The Jenex Corporation to Therma Bright Inc. as it completes R&D and readies its product for commercialization.)

TherOZap™ is the next generation in pain management relief using thermal therapy for insect bites and stings. The TherOZap™ thermal relief therapy aims to reduce the inflammatory response, relieving the symptoms of pain, itch and inflammation associated with over 20,000 different insect bites and stings.

TherOZap™ Ongoing Research

ZIKA Research:  Currently, Therma Bright has been working with engineers and designers to complete a prototype that will be tested for effectiveness against fighting and killing the Zika virus and other mosquito borne diseases.  Researchers have suggested that the Zika virus, and other mosquito borne disease stay in the area of the bite and/or sting for a limited period of time, before entering the blood stream and carrying the virus throughout the body. Our researchers believe that if the TherOZap™ thermal-based device is placed on the bite immediately following a bite/sting, the thermal heat can kill the virus prior to it spreading throughout the body. Once approved testing is complete, Therma Bright will seek to secure all regulatory approvals and certifications prior to beginning outsource manufacturing and sales distribution channels of the TherOZap™.